Gossamer Bio Financial Statements (GOSS)
|
|
Report date
|
|
|
24.03.2020 |
26.02.2021 |
03.03.2022 |
17.03.2023 |
05.03.2024 |
|
07.11.2024 |
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
112.1 |
Operating Income, bln rub |
|
|
-186.1 |
-234.0 |
-216.1 |
-218.6 |
-183.8 |
|
-62.8 |
EBITDA, bln rub |
? |
|
-186.1 |
-234.0 |
-209.3 |
-211.1 |
-172.2 |
|
-62.6 |
Net profit, bln rub |
? |
|
-180.8 |
-251.6 |
-249.1 |
-240.2 |
-179.8 |
|
-71.6 |
|
OCF, bln rub |
? |
|
-144.8 |
-176.4 |
-188.9 |
-187.0 |
-159.2 |
|
-1.41 |
CAPEX, bln rub |
? |
|
6.57 |
24.9 |
1.62 |
0.475 |
0.000 |
|
232.8 |
FCF, bln rub |
? |
|
-151.4 |
-201.2 |
-190.5 |
-187.5 |
-159.2 |
|
-1.35 |
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
OPEX, bln rub |
|
|
182.5 |
210.6 |
216.0 |
218.5 |
183.8 |
|
166.1 |
Cost of production, bln rub |
|
|
3.09 |
4.27 |
5.17 |
4.43 |
4.39 |
|
2.98 |
R&D, bln rub |
|
|
143.4 |
160.9 |
170.3 |
170.9 |
145.3 |
|
131.8 |
Interest expenses, bln rub |
|
|
0.000 |
12.7 |
19.4 |
13.9 |
13.5 |
|
12.0 |
|
Assets, bln rub |
|
|
426.6 |
539.4 |
343.7 |
272.5 |
311.9 |
|
350.9 |
Net Assets, bln rub |
? |
|
-334.2 |
-577.5 |
-811.5 |
-1 032 |
62.8 |
|
54.1 |
Debt, bln rub |
|
|
39.6 |
183.7 |
185.2 |
225.7 |
212.5 |
|
201.9 |
Cash, bln rub |
|
|
401.8 |
512.6 |
325.2 |
255.7 |
296.4 |
|
327.0 |
Net debt, bln rub |
|
|
-362.3 |
-328.9 |
-140.0 |
-29.9 |
-84.0 |
|
-125.2 |
|
Ordinary share price, rub |
|
|
15.6 |
9.67 |
11.3 |
2.17 |
0.913 |
|
0.510 |
Number of ordinary shares, mln |
|
|
54.7 |
68.5 |
74.8 |
84.6 |
152.6 |
|
226.3 |
|
Market cap, bln rub |
|
|
856 |
662 |
846 |
184 |
139 |
|
115 |
EV, bln rub |
? |
|
493 |
334 |
706 |
154 |
55 |
|
-10 |
Book value, bln rub |
|
|
-334 |
-578 |
-812 |
-1 032 |
63 |
|
54 |
|
EPS, rub |
? |
|
-3.30 |
-3.67 |
-3.33 |
-2.84 |
-1.18 |
|
-0.32 |
FCF/share, rub |
|
|
-2.77 |
-2.94 |
-2.55 |
-2.22 |
-1.04 |
|
-0.01 |
BV/share, rub |
|
|
-6.10 |
-8.43 |
-10.8 |
-12.2 |
0.41 |
|
0.24 |
|
EBITDA margin, % |
? |
|
|
|
|
|
|
|
-55.8% |
Net margin, % |
? |
|
|
|
|
|
|
|
-63.9% |
FCF yield, % |
? |
|
-17.7% |
-30.4% |
-22.5% |
-102.2% |
-114.3% |
|
-1.17% |
ROE, % |
? |
|
54.1% |
43.6% |
30.7% |
23.3% |
-286.5% |
|
-132.3% |
ROA, % |
? |
|
-42.4% |
-46.6% |
-72.5% |
-88.2% |
-57.6% |
|
-20.4% |
|
P/E |
? |
|
-4.73 |
-2.63 |
-3.40 |
-0.76 |
-0.77 |
|
-1.61 |
P/FCF |
|
|
-5.65 |
-3.29 |
-4.44 |
-0.98 |
-0.88 |
|
-85.4 |
P/S |
? |
|
|
|
|
|
|
|
1.03 |
P/BV |
? |
|
-2.56 |
-1.15 |
-1.04 |
-0.18 |
2.22 |
|
2.13 |
EV/EBITDA |
? |
|
-2.65 |
-1.43 |
-3.38 |
-0.73 |
-0.32 |
|
0.16 |
Debt/EBITDA |
|
|
1.95 |
1.41 |
0.67 |
0.14 |
0.49 |
|
2.00 |
|
R&D/CAPEX, % |
|
|
2 184% |
646.4% |
10 504% |
35 983% |
|
|
56.6% |
|
CAPEX/Revenue, % |
|
|
|
|
|
|
|
|
207.6% |
|
Gossamer Bio shareholders |